Redeye updates its estimates and valuation following Mentice’s Q4 2023 report. The quarter featured rather anaemic sales growth and profitability, though its order intake and M&A bode well for continued profitable growth. Mentice opportunistically acquired all substantial assets from competitor Biomodex, complementing its existing product offering. We judge the company’s long-term prospects remain essentially unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mentice Q4 2023 - Ability is nothing without opportunity

© Modular Finance, source Nordic Press Releases